Before revision:  We validate NaroNet using synthetic data simulating multiplex-immunostained images with adjustable probabilistic incidence of different TMEs . Then we apply our model to two real sets of patient tumors, one consisting of 336 seven-color multiplex-immunostained images from 12 high-grade endometrial cancers, and the other consisting of 372 35-plex mass cytometry images from 283 breast cancer patients .
After revision:  We validate NaroNet using synthetic patient cohorts with adjustable incidence of different TMEs . Then we apply our model to two real sets of patient tumors, one consisting of 336 seven-color multiplex-immunostained images from 12 high-grade endometrial cancers, and the other consisting of 372 35-plex mass cytometry images from 283 breast cancer patients .